GHP Family Pharmacy Customer Service 100 N. Academy Ave. Danville, PA 17822 Tel. • 855•552•6028 PA Relay 711 GeisingerHealthPlan.com



ANTIHEMOPHILIA AGENTS PRIOR AUTHORIZATION FORM (form effective 1/8/2024)

Prior authorization guidelines for **Antihemophilia Agents** are available on Geisinger Health Plan's website at https://healthplan.geisinger.org/pharmacy/pharmacy/pharmacy/strip=true&style=OneGeisinger

New request ☐Renewal request Tota	al # of pgs:	Prescriber name:				
Name of office contact:		Specialty:				
Contact's phone number:		NPI:		State license #:		
LTC facility contact/phone:		Street address:				
Beneficiary name:		City/State/Zip:				
Beneficiary ID#:	DOB:	Phone:	Phone:		Fax:	
CLINICAL INFORMATION.						
Drug #1 requested:			Strength & package size:			
Directions:			Quantity:		Refills:	
Drug #2 requested:			Strength & package size:			
Directions:			Quantity:		Duration:	
Diagnosis (submit documentation):			Dx code (<u>required</u>):			
Is the medication prescribed by a hematologist or hemophilia treatment center practitioner?						
Complete the section(s) below applicable to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.						
INITIAL REQUESTS						
1. Request is for HEMLIBRA (emicizumab):						
Has a diagnosis of severe congenital hemophilia A						
Has a diagnosis of congenital hemophilia A with inhibitors						
Has a diagnosis of congenital hemophilia A and a history of at least 1 spontaneous joint bleed or other serious bleeding event						
2. Request is for a BYPASSING AGENT (eg, FEIBA NF, NovoSeven, Sevenfact):						
☐Has hemophilia A with inhibitors AND:						
☐Is using the requested medication for episodic/on-demand treatment OR intermittent/periodic prophylaxis						
☐ Is using the requested medication for routine prophylaxis AND:						

GHP Family Pharmacy Customer Service 100 N. Academy Ave. Danville, PA 17822 Tel. • 855•552•6028 PA Relay 711 GeisingerHealthPlan.com



Failed to achieve clinical goals with Hemlibra (emicizumab)				
Has a medical reason why Hemlibra (emicizumab) cannot be used				
Has been using the requested bypassing agent for routine prophylaxis within the pa	st 90 days			
☐Has hemophilia B with inhibitors				
Has acquired hemophilia				
Has congenital factor VII deficiency				
Has Glanzmann's thrombasthenia				
3. Request is for a non-preferred FACTOR VIII, FACTOR IX, or VWF:				
☐Both of the following:				
☐ Has been using the requested medication within the past 90 days				
Has a medical reason to continue using the requested medication				
Failed to achieve clinical goals with or has a contraindication or an intolerance to the preferred FVIII, FIX, or FVIII/VWF				
medications with the same half-life (standard v. extended half-life), if applicable. Refer to https://papdl.com/preferred-drug-list for				
a list of preferred and non-preferred drugs in this class.				
☐ Has a diagnosis for which no preferred Antihemophilia Agents are appropriate. Refer to				

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.